On the HCPLive Atopic Dermatitis condition center page, resources on the topics of medical news and expert insight into eczema can be found. Content includes articles, interviews, videos, podcasts, and breaking news on dermatitis research, treatment, and drug development.
November 22nd 2023
These pivotal trial results from a study in China indicated the potential of this drug as a quarterly treatment for individuals with eczema.
November 19th 2023
October 30th 2023
October 21st 2023
Linda Stein Gold, MD, discusses the notable transition in topical therapies for both psoriasis and atopic dermatitis, with the introduction of effective FDA-approved nonsteroidal treatments.
In this interview, Dr. Simpson discussed the latest findings presented at EADV in Berlin on the use of tapinarof cream, 1% for adults and children as young as 2 years with eczema.
This new data resulted from the first study that found EIS could detect skin barrier dysfunction among children found to have developed atopic dermatitis early on in life.
The new educational initiative was launched to provide useful insights from dermatologists as well as personal accounts by patients with seborrheic dermatitis with many different backgrounds.
The sNDA was announced for roflumilast cream 0.15% to the FDA, and the formulation is said to not to be disruptive to the skin barrier or contain common irritants to patients’ skin.
These new results for tralokinumab could provide safer treatment options for older atopic dermatitis patients versus conventional therapies with greater risk of adverse events and drug-drug interactions.
In this latest research, the investigators noted that upadacitinib therapy may also be utilized as a treatment option for atopic dermatitis patients who experience a flare.
New late-breaking trial data from the ADhere, Adjoin, ADvocate1, and ADvocate2 trials showed solid results for lebrikizumab in treating moderate-to-severe atopic dermatitis.